These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 37102155)

  • 1. A pathway-based mutation signature to predict the clinical outcomes and response to CTLA-4 inhibitors in melanoma.
    Wang Q; Li X; Qiu J; He Y; Wu J; Li J; Liu W; Han J
    Comput Struct Biotechnol J; 2023; 21():2536-2546. PubMed ID: 37102155
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Homologous recombination repair gene mutations as a predictive biomarker for immunotherapy in patients with advanced melanoma.
    You Z; Lv M; He X; Pan Y; Ge J; Hu X; Zheng Y; Huang M; Zhou C; You C
    Front Immunol; 2022; 13():871756. PubMed ID: 35990677
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel pathway mutation perturbation score predicts the clinical outcomes of immunotherapy.
    Li X; He Y; Wu J; Qiu J; Li J; Wang Q; Jiang Y; Han J
    Brief Bioinform; 2022 Sep; 23(5):. PubMed ID: 36063561
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic treatments for metastatic cutaneous melanoma.
    Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
    Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of NOTCH4 mutation as a response biomarker for immune checkpoint inhibitor therapy.
    Long J; Wang D; Yang X; Wang A; Lin Y; Zheng M; Zhang H; Sang X; Wang H; Hu K; Zhao H
    BMC Med; 2021 Jul; 19(1):154. PubMed ID: 34284787
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A mutation-based gene set predicts survival benefit after immunotherapy across multiple cancers and reveals the immune response landscape.
    Long J; Wang D; Wang A; Chen P; Lin Y; Bian J; Yang X; Zheng M; Zhang H; Zheng Y; Sang X; Zhao H
    Genome Med; 2022 Feb; 14(1):20. PubMed ID: 35197093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A whole-blood RNA transcript-based gene signature is associated with the development of CTLA-4 blockade-related diarrhea in patients with advanced melanoma treated with the checkpoint inhibitor tremelimumab.
    Friedlander P; Wood K; Wassmann K; Christenfeld AM; Bhardwaj N; Oh WK
    J Immunother Cancer; 2018 Sep; 6(1):90. PubMed ID: 30227886
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Predictive Value of Tumor Mutation Burden on Clinical Efficacy of Immune Checkpoint Inhibitors in Melanoma: A Systematic Review and Meta-Analysis.
    Ning B; Liu Y; Wang M; Li Y; Xu T; Wei Y
    Front Pharmacol; 2022; 13():748674. PubMed ID: 35355708
    [No Abstract]   [Full Text] [Related]  

  • 9. Novel Molecular Determinants of Response or Resistance to Immune Checkpoint Inhibitor Therapies in Melanoma.
    Zhang W; Kong Y; Li Y; Shi F; Lyu J; Sheng C; Wang S; Wang Q
    Front Immunol; 2021; 12():798474. PubMed ID: 35087523
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eight gene mutation-based polygenic hazard score as a potential predictor for immune checkpoint inhibitor therapy outcome in metastatic melanoma.
    Zhao L; Luo T; Jiang J; Wu J; Zhang X
    Front Mol Biosci; 2022; 9():1001792. PubMed ID: 36120536
    [No Abstract]   [Full Text] [Related]  

  • 13. The Predictive Value of
    Ye T; Zhang JY; Liu XY; Zhou YH; Yuan SY; Yang MM; Xie WZ; Gao C; Chen YX; Huang ML; Ye CZ; Chen J
    Front Immunol; 2021; 12():785526. PubMed ID: 35069558
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.
    Shi Y; Lei Y; Liu L; Zhang S; Wang W; Zhao J; Zhao S; Dong X; Yao M; Wang K; Zhou Q
    Cancer Med; 2021 Apr; 10(7):2216-2231. PubMed ID: 33655698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NOTCH4 mutation as predictive biomarker for immunotherapy benefits in NRAS wildtype melanoma.
    Li H; Zhang Q; Duan Q; Tan Y; Sun T; Qi C
    Front Immunol; 2022; 13():894110. PubMed ID: 35967450
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive Value of the
    Pan YH; Zhang JX; Chen X; Liu F; Cao JZ; Chen Y; Chen W; Luo JH
    Front Immunol; 2021; 12():643282. PubMed ID: 34421886
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor Mutational Burden Predicting the Efficacy of Immune Checkpoint Inhibitors in Colorectal Cancer: A Systematic Review and Meta-Analysis.
    Li Y; Ma Y; Wu Z; Zeng F; Song B; Zhang Y; Li J; Lui S; Wu M
    Front Immunol; 2021; 12():751407. PubMed ID: 34659255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. mTOR pathway gene mutations predict response to immune checkpoint inhibitors in multiple cancers.
    Cheng L; Wang Y; Qiu L; Chang Y; Lu H; Liu C; Zhang B; Zhou Y; Bai H; Xiong L; Zhong H; Nie W; Han B
    J Transl Med; 2022 May; 20(1):247. PubMed ID: 35642038
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An antigen processing and presentation signature for prognostic evaluation and immunotherapy selection in advanced gastric cancer.
    Wang KW; Wang MD; Li ZX; Hu BS; Wu JJ; Yuan ZD; Wu XL; Yuan QF; Yuan FL
    Front Immunol; 2022; 13():992060. PubMed ID: 36311733
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.